Skip to main content

Table 5 Scenario analysis results

From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

Results for carbapenem-sparing scenario where non-carbapenem drugs are given precedence Ceftolozane/tazobactam Piperacillin/tazobactam Incremental
Ceftolozane/tazobactam - Piperacillin/tazobactam
 Total costs per patient (USD 2015) $36,416 $36,038 $378
 Total QALYs (discounted) per patient 9.19 9.13 0.06
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained)    $6020
Results using only nosocomial isolates Ceftolozane/tazobactam Piperacillin/tazobactam Incremental
Ceftolozane/tazobactam - Piperacillin/tazobactam
 Total costs per patient (USD 2015) $42,737 $42,358 $378
 Total QALYs (discounted) per patient 12.37 12.27 0.10
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) - - $3825
Results for high risk patients (aged 65 years, requiring an ICU stay or catheter-associate infection) using nosocomial isolates Ceftolozane/tazobactam Piperacillin/tazobactam Incremental
Ceftolozane/tazobactam - Piperacillin/tazobactam
 Total costs per patient (USD 2015) $37,947 $37,557 $390
 Total QALYs (discounted) per patient 10.10 10.03 0.07
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) - - $6037
Results when lifetime health care expenditure for health survivors is excluded Ceftolozane/tazobactam Piperacillin/tazobactam Incremental
Ceftolozane/tazobactam - Piperacillin/tazobactam
 Total costs per patient (USD 2015) $7762 $7583 $179
 Total QALYs (discounted) per patient 9.19 9.13 0.06
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) - - $2842
  1. QALY Quality-adjusted life year